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Abstract
A number of infectious diseases are known to be caused by microorganisms resulting in death and
impairment. Understanding the principle behind the emergence of the disease and the reason for the
multi-drug resistance of these pathogenic microorganisms is crucial, in order to develop an anti-infective
against these pathogens. Our work was to develop an antimicrobial drug against a Shikimate pathway
enzyme and to design inhibitors against the Plasmodium parasite’s Orotidine 5’-monophosphate
decarboxylase (OMPDC) enzyme. We also attempted to decipher the OMPDC-catalyzed mechanism on
a 3-keto-L-gulonate 6-phosphate decarboxylase (KGPDC) scaffold, as a means of understanding the
mechanism in detail. In the first part of the thesis, the enzyme 3-dehydroquinate synthase from
Enterococcus faecalis was expressed and purified and tested for its activity. A number of modifying
enzymes were also cloned, and attempts were made to express and purify them, for use in the
modification of side chains of the inhibitors in the process of combinatorial biosynthesis. The second
part of the thesis was a two-pronged approach, where, initially we attempted to understand the
mechanism catalyzed by OMPDC by replicating it on the scaffold of its related suprafamily member,
KGPDC. By understanding the mechanism, we hoped to develop inhibitors against the OMPDC enzyme
of the pathogens. Complementation growth studies were performed and the aerobic growth curves were
plotted. In the last part of the thesis, we tried to find the disparity between the human and Plasmodium’s
OMPDC enzymes with which we looked forward to a rational design of an inhibitor against
Plasmodium OMPDC, hoping that this inhibitor might have a minimal side-effect on the human host if it
is developed in to a drug. We found a number of key residues that were distinct between the human host
and the pathogen and we propose that if these differing residues can be targeted to develop an efficient
drug against the Plasmodium OMPDC enzyme, consequently, the drug might have a minimal attack if




ESPS 5-enolpyruvyl shikimate-3-phosphate synthase
EfaroB 3-dehydroquinate synthase from Enterococcus fecalis
DHQS 3-dehydroquinate synthase
VRE Vancomycin resistant Enterococcus
NAD+ Nicotinamide adenine dinucleotide
NADH Nicotinamide adenine dinucleotide reduced
Zn 2+ Zinc
Co 2+ Cobalt
PCR Polymerase chain reaction
CIAP Calf intestine Alkaline phosphatase
NEB New England Biolabs




SDS Sodium dodecyl sulphate
PAGE polyacrylamide gel electrophoresis
ONPG O-nitrophenyl- β-D-galactopyranoside
OMPDC Orotidine-5’-monophosphate decarboxylase
KGPDC 3-keto L-gulonate 6-phosphate decarboxylase
HPS D-arabino-hex-3-ulose 6-phosphate synthase






EO 1-(erythrofuranosyl) orotic acid
OPRT orotate phosphoribosyltransferase
Aza-UMP 6-azauridine 5'-monophosphate
1Part 1: Towards the development of inhibitors against the Shikimate pathway
enzyme, 3-dehydroquinate synthase
2Chapter 1: Introduction
1.1 Drug Resistance- A serious threat
Antibacterial agents are compounds that either halt or completely inhibit the growth of
bacteria. Although there are several antimicrobials developed against the pathogenic species, the
growing number of multi-drug resistant pathogens poses a serious health threat to humans. There
is a pressing need for new drugs to be developed against these emerging drug-resistant
microorganisms. The microbes exhibit various modes of drug resistance [56], such as:
1) Drug inactivation or modification.
2) Alteration of target site.
3) Alteration of metabolic pathway.
4) Reduced drug accumulation. [1]
An important research interest centers on bringing about the alteration in bacterial
growth, which can be accomplished by modulating the flux of biochemical pathways, which in
turn result in a cascade of events leading to stasis or complete disruption of cell function and
growth. One such biochemical pathway that serves as an interesting area of research for potential
antibacterial and antifungal agents is the Shikimate pathway. The enzymes of the Shikimate
pathway are the prime targets for drug design as the pathway is essential in plants and microbes,
but absent in humans, consequently reducing the risk of potential adverse effects from drugs that
inhibit this pathway.
31.2 Enzymes in the shikimate pathway
The Shikimate pathway comprises of seven enzymatic steps, ultimately, giving rise to the
precursors of the aromatic amino acids such as phenylalanine, tyrosine and tryptophan [2]. The
biosynthesis of these amino acids is vital for the homeostasis of various plants, fungi and bacteria
[3]. In addition, this biochemical pathway generates aromatic precursors essential for folic acid
(p-aminobenzoic acid) and ubiquinone production [4].
A total of seven enzymes are responsible for the conversion of phosphoenol pyruate
(PEP) and erythrose 4-phosphate (E4P) to chorismate (Figure 1.1). Chorismate plays a key role
as it branches in to three pathways (Figure 1.2) - the first pathway leading to the biosynthesis of
phenylalanine and tyrosine, the second pathway leading to tryptophan biosynthesis and the third
pathway leading to folate and ubiquinone biosynthesis[2].
The first step of the shikimate pathway comprises of the condensation of the glycolytic
intermediate, Phosphoenol pyruate (PEP), a three-carbon compound and the Pentose Phosphate
pathway intermediate, D-erythrose 4-phosphate, a four-carbon compound to give rise to a seven-
carbon 6-membered heterocyclic compound, 3-deoxy-D-arabino-heptulosonate 7-phosphate
(DAHP). In the second step, the ring oxygen is exchanged for the exocyclic C7 of DAHP to form
a highly substituted cyclohexane derivative (Garner & Hermann, 1984), 3-dehydroquinate [3].
The remaining five steps serve to introduce a side chain and 2 double bonds to the cyclohexane
ring. The end product of the Shikimate pathway, Chorismate, becomes a precursor substrate for
various primary and secondary metabolites through a series of anabolic catalytic sequences.
4Figure 1.1: The seven enzymatic reactions of the Shikimate Pathway.  The condensation
reaction between PEP and D-erythrose 4-phosphate culminates in chorismate production.
1.3 Essentiality of the shikimate pathway
These aromatic amino acids not only serve as structural units of proteins, but also in turn,
serve as precursors to a range of secondary metabolites with aromatic ring structures, including
flavonoids, Vitamin K and lignin [3]. In plants, this pathway provides precursors for the
biosynthesis of various polyketides such as chalcones, stilbenes and flavonoids. These plant
polyketides are bioactive plant secondary metabolites that have a number of biological
5reactivities, including anti-microbial, anti-inflammatory, and anti-cancer activities; many of these
metabolites act as phytoalexins, plant antibiotics that target crucial metabolic pathways of
disease producing microbial pathogens. Natural product libraries can be used to screen for
effective lead compounds in the process of drug discovery and development.
Primary metabolites such as quinones, which are an essential components in the Electron
Transport Chain (ETC), are derived from Chorismate metabolism. In addition, signaling
molecules such as phenyl propanoids are some of the products derived downstream of the
reaction. It is therefore apparent that the shikimate pathway is crucial and vital for the survival of
bacteria, fungi, apicomplexan parasites and plants [3].
6Figure 1.2: Metabolic fates of Chorismate. The end product of the Shikimate pathway,
Chorismate, branches in to a number of secondary metabolites as shown in the above schematic
representation [2, 3].
1.4 Shikimate pathway as a viable drug target
The Shikimate pathway’s exclusivity and essentiality in bacteria, plants and fungi has
been one of the key rationales for choosing this pathway as a target for the design of herbicides
and antimicrobial compounds. It was suggested by Hermann and Weaver (1999) that the absence
7of this pathway in humans might minimize unwanted side-effects on humans, should the
inhibitors against the Shikimate pathway be developed as drugs or therapeutics [5].
An interesting fact about this pathway is that unlike other pathways, there is no individual
enzyme that can be termed “crucial” and that, all the enzymes are required for the
microorganisms and plants bearing the pathway. In spite of the fact that this pathway can be used
as a viable target for drug design, there are no known inhibitors, except for the commercial
herbicide, Glyphosate. Glyphosate targets the sixth enzyme, 5-enolpyruvyl shikimate-3-
phosphate synthase (ESPS), catalyzing the conversion of Shikimate 3-phosphate to 5-
enolpyruvyl shikimate-3-phosphate.  Thus, one of the aims of our project centers on the
biosynthesis of inhibitors targeting the enzyme 3-dehydroquinate synthase (DHQS) from the
microorganism Enterococcus faecalis (EfaroB), in the Shikimate pathway.
1.5 Known inhibitors of the pathway
Previously, various studies have been reported by researchers targeting the Shikimate
pathway as a potential novel drug target, including the drug resistant Mycobacterium
tuberculosis [6] which causes tuberculosis; Helicobacter pylori, the causative agent of gastric
cancer [7, 8] and gastrointestinal illness; Bacillus antharacis [9], the pathogen of Anthrax acute
disease; and the apicomplexan parasite Plasmodium falciparum, which causes the life
threatening malarial fever [10]. Although many drug targets have been identified, very few
targets have been successfully inhibited.  A few identified inhibitors of the Shikimate pathway
are shown in Figure 1.3.
8Figure 1.3: Inhibitors of Shikimate pathway enzymes. Inhibitors of DAHP Synthase (DAHPS)
are indicated by a and b. Carbaphosphanate which inhibits the 3-dehydroquinate synthase
(DHQS), and Glyphosate, the commercially available inhibitor to the first enzyme of the
pathway, DAHP Synthase are also illustrated in the figure.
1.6 Specific Aims of the Project
The project aims to develop anti-microbial compounds targeting the Shikimate pathway
of Enterococcus fecalis, through the combinatorial biosynthesis of novel compounds for further
development as inhibitors against the enzymes of Shikimate pathway.
1.7 Enterococcus faecalis- A clinical  pathogen
Enterococcus fecalis is a gram-positive cocci and a common commensal of the human
intestine. This microorganism is noted for its resistance to a number of antibiotics, including
vancomycin, the “drug of last resort”; hence this pathogen is also clinically known as
Vancomycin-Resistant Enterococcus (VRE). Opportunistic clinical infections caused by this
9pathogen include UTI (Urinary tract infection), bacteraemia, bacterial endocarditis, diverticulitis
and meningitis, sometimes leading to fatality. The high level of antibiotic resistance found
in Enterococcus is one factor that might probably contribute to its pathogenicity.
1.8 Enzyme mechanism catalyzed by DHQS from Enterococcus faecalis
The focus of this project is on the enzyme 3-dehdyroquinate synthase (DHQS), the
enzyme catalyzing the second step in the Shikimate pathway. The EfaroB catalyzes the
conversion of 3-deoxy-D-arabino- heptulosone 7-phosphate in to 3-dehydroquinate (fig 1.4). The
enzyme requires catalytic amounts of NAD+ and a divalent metal cation for its activity. For the
bacterial DHQS enzyme, Co2+ and Zn2+ are required for enzymatic activity. The E. coli enzyme
catalyzes a reaction involving an intramolecular oxidation reduction at C5 of DAHP (the
substrate of DHQS) with very tight binding of the NAD+ cofactor, the syn- elimination of
phosphate, and an alicyclic ring formation. Studies have indicated that the enzyme DHQS
catalyzes a redox reaction, with the other identified steps in the overall reaction mechanism
proceeding spontaneously. It is also noteworthy that there is no known structural data for the
orthologues of this enzyme from Enterococcus fecalis.
The EFaroB (Enterococcus fecalis dehydroquinate synthase) has a molecular weight of
39213.8 Da (Protparam). It requires NAD+ as cofactor and divalent metal ions, Zn 2+ and Co 2+
for activity. DHQS is a dimer with two domains in each monomer. DHQS, as supposed, utilizes
a complex multi-step mechanism which includes alcohol oxidation, phosphate β-elimination,
carbonyl reduction, ring opening and intramolecular aldol condensation (Mary, 2006).
Multi-drug resistant Enterococci and vancomycin-resistant Enterococci (VRE), in
particular, are opportunistic pathogens and major causes of nosocomial infections in
10
immunocompromised patients. There is currently no known inhibitor targeting the enzyme 3-
dehydroquinate synthase.
Figure 1.4: The 3-dehydroquinate synthase (aroB)-catalyzed reaction. EFaroB converts 3-
deoxy-D-arabino-heptulosone 7-phosphate to 3-dehydroquinate with the reduction of NAD+ to
NADH.
1.9 Natural products as EfaroB inhibitors
Screening of natural products for inhibitors was adopted as an initial strategy as this has
been proven to be a successful and valuable source of infective agents. Furthermore, screening of
natural product libraries usually creates a higher percentage of bioactive hits in comparison to
chemical libraries. Finally natural products reveal previously unknown structure-bioactivity
relationships (Floss, 2006) [11].
The Flavonoid biosynthetic pathway is one of the best-characterized pathways in plants.
This pathway produces the major secondary plant metabolites and many of the flavonoids have
been shown to have anti-microbial, antioxidant, anti-inflammatory, and many other beneficial
properties [12]. The Flavonoid pathway also serves as an attractive target for metabolic
engineering [13].
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Chapter 2: Materials and Methods
2.1 Materials
All reagents were purchased from Sigma-Aldrich and were of highest quality grade
commercially available, unless otherwise stated. Reagents for performing first strand cDNA
synthesis and Polymerase chain reaction (PCR) were from Invitrogen. The primers for normal
PCR and Quikchange mutagenesis were ordered from Sigma Life sciences. Restriction enzymes
and their corresponding buffers were purchased from New England Biolabs (NEB) and Calf
intestinal Alkaline Phosphatase (CIAP) was purchased from Promega. The vectors are purchased
from Novagen. T4 DNA ligase was purchased from New England Biolabs. The Quikchange
mutagenesis kit was purchased from Stratagene. The gel extraction kit and miniprep kit for
isolation of plasmid DNA were purchased from Qiagen.
2.2 Cloning protocol
A typical PCR mixture (100 µL) contained 1 ng of cDNA, 10 µL of 10X Pfx
amplification buffer, 1 mM MgSO4, 0.2 mM of each of the four dNTPs (dATP, dGTP, dCTP,
dTTP), 20 pmol of each primer (forward and reverse) and 2.5 U of Pfx DNA polymerase
enzyme. The genes were amplified using the following parameters: 94 OC for 2 min, followed by
40 cycles of 94 OC for 1 min, an annealing temperature for 55 OC for 1 min 15 sec, extension at
68 OC for 3 min and a final extension of 68 OC for 10 min. The PCR amplified products were run
on a 1% agarose gel and the correct band was excised using a scalpel and subjected to gel
purification to extract the pure insert using a Qiagen gel extraction kit. The concentration of the
insert was determined by the UV-Vis Spectrophotometer or using GE’s NanovueTM
Spectrophotometer. A double digestion usually follows which can be simultaneous or sequential.
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In sequential double digestion, a first digestion is performed at 37 OC for 3 hours. This is
followed by a quickQIA spin purification using the buffers PB and PE and a purple spin column
(Qiagen gel extraction kit). The second digestion can be done at 37 OC for overnight and the
double digested reaction mixture is purified with 1% agarose gel electrophoresis and Qiagen gel
extraction kit. A similar treatment is applied to the vectors by double digesting and the
appropriately restricted vector is treated with alkaline phosphatase (CIAP) to dephosphorylate
the 5’- phosphate ends to prevent re-circularization and incubated at 37 OC for 30 min. Ligation
is carried out at 15 OC overnight using the double digested insert and the CIAP treated vector.
After ligation, the mixture was drop dialyzed against double distilled water using a Millipore
0.025µ VSWP filter membrane for 30 min at room temperature  and transformed in to XL1Blue
electrocompetent cells and plated on to LB agar plates supplemented with 100 µg/mL ampicillin
followed by incubation at 37 OC overnight. The plasmids were extracted using the Qiagen’s
miniprep kit and the correct clones were identified by sequencing with T7 forward and T7
reverse primer. Sequencing was done with the AITBiotech.
2.3 Production of electrocompetent cells
We used three E.coli strains of electrocompetent cells for our studies, namely E.coli XL1-
Blue, BL21 (DE3) cells (stratagene) and Rosetta-gami TM 2 . The cultures were grown in 2 L
flasks containing 1 L LB broth., and were inoculated with 2 mL of overnight cultures. XL1-Blue
was grown in the presence of 20 µg/mL of tetracycline, E.coli BL21 was grown in the absence of
any antibiotic and Rosetta was grown in the presence of 25 µg/mL of chloramphenicol. Cultures
were grown until OD600 reaches 0.5 (mid-log phase). All the following steps were carried out at 4
OC. The culture was cooled on ice for 20 min and centrifuged at 4000 x g for 15 min. The cell
13
pellet was resuspended in 1 L of ice-cold sterile double distilled water and centrifuged at 4000 x
g for 15 min. This step is again repeated twice with ddH2O and centrifuged at same speed. The
cell pellet was resuspended in 40 mL of 10% glycerol and centrifuged at 4000 x g for 10 min.
The cell pellet was resuspended with a final volume of 4 mL of 10% glycerol and 60 µL of the
suspension is aliquoted in to eppendorfs and stored at -80 OC.
2.4 Protein Expression and purification
A large scale purification of the proteins were performed in E.coli BL21 cells, unless
otherwise stated. The correct gene insert verified after sequencing is transformed in to BL21
expression cell lines and an overnight culture was grown in LB broth supplemented with 100
µg/mL of ampicillin. This was transferred to large scale flasks containing 1 L LB broth
supplemented with 100 µg/mL of ampicillin and allowed to reach an OD600 = 0.6 and induced
with 0.5 mM IPTG(isopropyl β-D- thiogalactosidase) for 4 hours at 37 OC with constant shaking
at 220 rpm. The cells were harvested by centrifugation at 6000 rpm for 10 min at 4 OC. The
supernatant was discarded and the pellet was resuspended in 60mL of 1x Lysis buffer (5 mM
imidazole, 500 mM NaCl, 5 mM MgCl2, 20 mM Tris-HCl, pH7.9). The cell pellet was lysed by
sonicated and clarified by centrifugation at 18000 rpm for 45 min at 4 OC. The supernatant
containing the His-tagged proteins was purified with a chelating Sepharose column charged with
Ni2+. The fractions containing the proteins were pooled, dialyzed in the buffer containing 20 mM
Tris-HCl, 100 mM NaCl, pH 8. The purified protein was concentrated using an Amicon Ultra
centrifugal filter device and stored at -80 OC.
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2.5 Cloning, expression and purification of dehydroquinate synthase
(DHQS) from Enterococcus fecalis (EFaroB)
The EFaroB enzyme was cloned in Tom15b (containing 10x His-tag, a modification of
pET15b), expressed and purified by a fellow colleague with the following parameters for
purification. The cells were induced with 0.1 mM IPTG (isopropyl β-D- thiogalactosidase) for 8
hours at 37 OC. All the other steps were as previously reported in section 2.4. The purified
protein was tested for its enzyme activity using the coupled enzyme assay.
2.6 Coupled enzyme Assays of EFaroB and EFaroF
For the ease of detection and screening, we couple the enzymes that catalyzes the first
two steps of the pathway to calculate the rate of enzyme reaction. The assay for aroB was
coupled to the first enzyme of the pathway, aroF (3-deoxy-D-arabino heptulosonate 7-phosphate
synthase) using a diaphorase-catalyzed reaction (Figure 2.1). Diaphorase utilizes the cofactor
turnover of NAD+ and this oxidation of NADH (reduced nicotinamide adenine dinucleotide) to
NAD+ (Nicotinamide Adenine dinucleotide) is monitored at 340 nm (ε= 6220 M-1 cm-1) by UV-
2550 Spectrophotometer (Shimadzu).
A standard diaphorase-catalyzed assay mixture contains 50mM K+ HEPES buffer
(pH7.5), 1.5mM NAD+, 1.5mM INT (Indole-nitrotetrazolium violet) in DMF, 0.05U Diaphorase,
1.5mM phosphoenol pyruate (PEP), 1.5mM D-erythrose 4-phosphate and varying levels of
EFaroB (13.6 mg/mL) and 5 µL of DAHP Synthase (aroF). The final reaction volume was
100µL and the reaction was conducted in a 200µL Quartz cuvette.
15
Figure 2.1: Schematic of the coupled-enzyme assay for EFaroB. The turnover of NADH to
NAD+ is monitored at 340 nm using a colorimetric detection assay. In this process the cofactor
turnover of NADH is coupled to the enzyme Diaphorase which converts the reduced indole-
nitrotetrazolium violet (INT) to oxidized indole-nitrotetrazolium violet (INT).
2.7 Identification of potential inhibitors of aroB
We wanted to identify the potential chemical moieties with inhibitory activities against
EFaroB. Using an initial library of 153 polyketide-based flavonoid compounds (Appendix 2)
available in the laboratory, we screened our enzyme against the available library of compounds
for potential inhitors of EFaroB.  Upon identifying compounds with inhibitory activities, we
INTINT
(Detected at 340 nm)
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would proceed with modifying the functional groups and subsequent combinatorial biosynthesis
of lead compounds based upon the insights obtained from the prior studies, for the development
of novel drug compounds.
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Chapter 3: Results for EfaroB purification
3.1 SDS-PAGE
The molecular weight of EFaroB in Tom15b is 39213.8 Da. As seen in Figure 3.1, SDS-
PAGE shows the purified protein and also the second lane showing the over-expressed protein in
supernatant fraction. The protein was purified using Nickel- affinity column as the 10x His-Tag
binds strongly to the divalent ion. Not much of target protein was detected in wash fractions and
most of the protein was eluted between the 6th to 18th fractions. The final concentration after
dialysis was 13.6 mg/mL.
Figure 3.1: SDS-PAGE results for large scale purification of EFaroB using Tom15b vector. M-
Marker; P- Pellet; S- Supernatant; F (F3, F4, F5)- Wash fractions; A5, A6, A7, B10- Elution
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3.2 Assay Results of EfaroB
The purified protein was tested for its activity by coupling with aroF (from E. fecalis) in the
presence and absence of 100mM ZnCl2. There was no activity detected. Even when the enzyme
was coupled to SST (DHQS from E.coli), no activity was detected. We came to a conclusion that
our recombinant enzyme was inactive, presumably due to the lack of a suitable purification
procedure.
3.3 Screening for inhibitors
Since there was no activity detected in EFaroB we could not proceed further with
inhibitor screening.
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Chapter 4: Cloning and expression of enzymes for combinatorial biosynthesis
4.1. Combinatorial Biosynthesis
The fundamentals of combinatorial biosynthesis is to combine genes from different
organisms and designing a new set of gene clusters to produce bioactive compounds, leading to
the diversification of chemical and natural product libraries. This is done via improvement of
enzyme function, alteration of substrate specificities and introduction of novel catalytic
activities. Combinatorial biosynthesis can also be used in better production of natural compounds
and generation of novel compounds with unique structure and function [13].
The idea of combinatorial biosynthesis is not new; this biosynthetic method has been
researched by Horinouchi (2008), in which the focus is on the biosynthesis of non-bacterial and
unnatural flavonoids, stilbenoids and circuminoids in an E.coli cell.
In our attempt, we wanted to create diversified libraries in our by assembling all the
enzymes (from different sources) in a matrix and to add polyketide precursors for precursor-
directed biosynthesis [13]. In addition, wild type enzymes can be pooled and employed in the
biosynthesis, and directed evolution of enzymes can be performed to incorporate new and novel
enzyme functions.
4.2 Enzymes for combinatorial biosynthesis
In this project, 10 genes were selected to be cloned, expressed and purified for their use
as modifying enzymes in the process of combinatorial biosynthesis. These genes were selected
on the basis of ease of cloning, availability of cDNA and many other factors. 9 genes were from
the plant Arabidopsis thaliana, and one was from Pseudomonas aeruginosa. Genes from
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Arabidopsis included the chalcone isomerases (CI, CI2, CI3, CI4, CI5, TT5), DMR6 (downy
mildew resistant gene), leucoanthocyanidin dioxygenase (LDOX), hydroxy cinnamoyl
transferase (HCT) and the gene from Pseudomonas is Polyketide synthase (PhID).
4.2.1 Chalcone isomerases
4.2.1.1 Amplification of Chalcone isomerases from Arabidopsis
cDNA was extracted from Arabidopsis using the Superscript first strand synthesis kit
purchased from Invitrogen. The standard procedure for amplification and cloning was followed
as mentioned earlier for EfaroB in chapter 2.
4.2.1.2 Cloning of Chalcone isomerases
Following this the genes were cloned into different vectors such as pET15b, Tom15b and
pET17b. Both the genes and the vectors were digested with NdeI and BamHI, with an additional
step of phosphatase treatment to the vectors. After digestion, ligation is performed at 15 ̊C
overnight with the same conditions mentioned for EFaroB. Cloning was also done with pET20b
vector using different restriction enzymes NdeI and XhoI and ligation was performed.
4.2.1.3 Expression and Solubility Screening Studies
The ligation product was then dialyzed for 30 minutes in sterile water before
transformation into XL1-Blue cells. After transformation, the correct inserts were verified by
sequencing the extracted plasmids. These correct inserts were transformed into BL21 and
Rosetta 2 competent cells.
In order to screen for protein expression and solubility, constructs were grown overnight
in 10 mL LB broth containing the appropriate antibiotics. The overnight cultures were scaled-up
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and grown up to OD600=0.6. One half of the overnight culture was induced with varying
concentrations of IPTG starting from 0.1 mM to 0.5 mM and induced for different time intervals
ranging from 1 to 18 hours. The other half that was uninduced served as a control. The cells were
harvested by centrifugation at 6000rpm for 10 min and the supernatant was discarded.  The pellet
was resuspended in 500 µL of 1X lysis buffer on ice and the cells were lysed by a 550 Ultrasonic
Dismembrator (MISONIX HEAT SYSTEMS) at an amplitude of 10% for a total process time of
1 min. The lysed cells were centrifuged at 14000rpm for 10 min at 4 OC. The pellet and
supernatant were taken in separate eppendorf tubes and the pellet was resuspended in 500 µL of
1X lysis buffer. The induced and uninduced samples were analyzed by electrophoresis on a 15%
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) gel.
Screening was also done at different temperatures (37 OC, 25 OC and 15 OC, respectively)
and also in M9 minimal medium. IPTG concentrations as low as 0.01mM to as high as 0.5mM
were used for the screens.
4.3 DMR6
The gene for DMR6 is a downy mildew resistant gene that has been characterized in
Arabidopsis plant. This gene belongs to the 2-oxoglutarate (2-OG) – Fe (II) oxygenase family.
The expression of this gene is induced during plant defense. There has been a statement that
DMR6 negatively affects plant defense [14]. Despite its recognition as an important gene during
plant defense, its exact function is still enigmatic [15].
4.3.1 Cloning, Expression and Screening for solubility in DMR6
All the procedures followed for gene cloning, protein expression and solubility screening
was the same as mentioned in section 4.2 for chalcone isomerase. The selection of vectors was
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also the same, except that the restriction site for pET20b is NdeI and SalI instead of NdeI and
XhoI.
4.3.2 Enhancing solubility using β-galactosidase α-complementation
Based on the proposal which states that there exists a strong correlation between β-
galactosidase activity and solubility of a protein (Wigley, 2001), we attempted to perform a
Quikchange PCR for the vector pMALc4x by inserting two basepairs after the SalI restriction
site. This was named as pMALc4xA2. The gene cloned in to pET20b was re-cloned in to
pMALc4xA2. The gene would be in frame (translational reading frame) with the α-fragment of
lacZ gene. Hence the α-fragment fuses with the C-terminal of the target gene thereby increasing
its solubility. The α-fragment interacts with the ω-fragment that commonly occurs in the
cytoplasm and the protein is pulled to the supernatant and visible blue colour colonies will be
observed on x-gal plates. If there is no interaction, the protein will be present in the insoluble
pellet fractions.
In an attempt to improve the protein solubility, random mutant libraries were created
using Mutazyme ® II DNA polymerase. As amplification was carried out using T7 promoter and
T7 terminator primers which anneal to sequences in the vector, approximately 200 base pairs
were added to the original gene sequence. These are cleaved off after digestion with the
restriction enzymes NdeI and SalI, as previously used for the original gene. The mutant vector
containing the gene in-frame with the random mutated gene was ligated and transformed after
restriction with their respective vectors. This was plated onto X-gal plates.
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4.4.1 Leucoanthocyanidin Dioxygenase (LDOX)
Leucoanthocyanidin dioxygenases (LDOX) is characterized as a “late gene” in  the
flavonoid biosynthesis pathway. These enzymes are involved in catalyzing the conversion of
leucoanthocyanins to anthocyanins [16] as shown in the Figure 4.1.
Figure 4.1: Reaction catalyzed by Leucoanthocyanidin dioxygenase (LDOX). The
leucoanthocyanidins are converted to anthocyanidins.
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4.4.2 Methods
4.4.2.1 Amplification and Cloning
The methods for amplification and cloning of LDOX were the same method as followed
for other genes mentioned previously.
4.4.2.2 Expression of LDOX in pET15b
LDOX was initially cloned into Tom15b. Later the LDOX was cloned into pET15b and
the expression was followed according to the method mentioned by Wilmouth (2001) in his
paper [17] and also a solubility screen was performed.
Figure 4.2: Amplification results of LDOX. The left lane contains the 1kb DNA marker and the
highlighted bands shows the result of LDOX which is nearly 1100 bp in size.
4.5.1 Hydroxy cinnamoyl transferases (HCT)
Hydroxy cinnamoyl transferase is involved in the phenyl propanoid pathway. The
silencing of this gene affects the lignin pathway in plants, and also the metabolic flux is diverted
by accumulation of Flavonoid compounds [18]. HCT catalyzes the transfer of functional groups




Figure 4.3: Reaction catalyzed by Hydroxy cinnamoyl transferase shows that the gene transfers
the functional groups in the reaction. In the above reaction, HCT is shown to transfer coumaroyl
and caffeoyl groups. This picture was adopted from Besseau, 2007 [15].
4.5.2 Amplification and Cloning in to Tom15b
The methods for amplification and cloning of HCT were the same method as followed for
other genes mentioned previously.
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Chapter 5: Results and Discussion
5.1 Chalcone Isomerases
Chalcone isomerases are also called chalcone-flavanone isomerase due to the reaction
they catalyse. These enzymes participate in the flavonoid biosynthesis pathway [19-22] in the
isomerisation reaction, thereby converting a chalcone to a flavanone. The reaction is shown
below in figure 5.1.
Figure 5.1: Isomerization reaction catalyzed by Chalcone Isomerase results in the conversion of
chalcone to flavanone. This figure is adopted from Shimada, 2003 [16].
The sequences and the corresponding sizes of Chalcone isomerases is given in Appendix
1. Out of the 6 Chalcone isomerases, only 2 (CI3 and CI4) were successfully amplified and of
these only CI3 was cloned and expressed.  CI3 has a molecular weight of 32 kDa. It was cloned
into four different vectors pET15b, pET17b, Tom15b, pET20b. The plasmid bearing the gene
encoding for CI3 was transformed into BL21 and Rosetta2. It was seen that of all these vectors,
CI3 seems to have a better expression pattern with pET20b vector. There was relatively low level
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expression noticed with pET17b, pET15b and Tom15b. Compared to the supernatant, the protein
was found to be over-expressing in the pellet, rendering it to be an insoluble protein.
Figure 5.2: Amplification result of the chalcone isomerase, CI3 shown in third and fourth lane
followed by a 1KB marker in the fifth lane. The size of CI3 corresponds to nearly 1kb.
Figure 5.3: Amplification result of TT5 shown in fourth and fifth lane, the size corresponding to






Figure 5.4: Expression results of CI3 in Tom15b and Rosetta2. From left, Ladder, first clone -
Uninduced pellet (UIP1), Uninduced Supernatant (UIS1), Induced pellet (IP1), Induced
Supernatant (IS1). A second clone containing UIP2, UIS2, IP2 and IS2 is shown in lanes 6, 7, 8
and 9 respectively.
Figure 5.5: Solubility screening of CI3-1 in Tom15b and M9 medium after 1 and 2 hours of
induction with 0.5 mM IPTG. From left, UIP1, UIS1, IP1, IS1 after 1 hour, UIP2, UIS2, IP2, IS2
after 2 hours, UIP3 after 3 hours induction, followed by protein marker.
L UIP1 UIS1 IP1 IS1 UIP2 UIS2 IP2 IS2
UIS1 IP1UIP1 IS1 UIP2 UIS2 IP2 IS2 LUIP2
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Figure 5.6: Screening of CI3-2 in Tom15b and M9 medium. Ladder, UIS3, IP3, IS3 after 3
hours, UIP6, UIS6, IP6, IS6 after 6 hours induction, UIP12, UIS12 after 12 hour induction.
Figure 5.7: Screening of CI3-3 in Tom15b and M9 medium. From left, IP12 and IS12 after 12
hours induction at 37 OC, ladder (L),  induction at 25 OC for UIP_1, UIS_1, IP_1, IS_1,  UIP_2,





























Figure 5.8: Screening of CI3-4 in Tom15b and M9 medium at 25 OC. IP_2, IS_2, UIP_3, UIS_3,
protein marker (L), IP_3, IS_3, UIP_6, UIS_6, IP_6. The numbers indicate the hours of
induction.
Figure 5.9: Screening of CI3 in pET20b and M9 medium. From left, marker, UIP_1, UIS_1,






































Figure 5.10: Screening of CI3 in pET20b and M9 medium at 37 OC. The first lane indicates the
marker followed by uninduced pellet (UIP), uninduced supernatant (UIS), induced pellet (IP) and
Induced Supernatant (IS) after 3 hours of induction with 0.5 mM IPTG. Lane 6-9 contains
duplicates of the CI3-pET20b clone.
Figure 5.11: CI3 in pET20b transformed in to BL21 and overexpressed in LB at 37 OC. From
left Ladder, UIP_1, UIS_1, IP_1, IS_1, UIP_2, UIS_2, IP_2, IS_2. The numbers following
indicate the respective induction time.




















Figure 5.12: CI3 in pET20b and Rosetta2 induced with 0.5mM IPTG. From left, ladder, UIP,
IP, UIS, IS after 3 hours of induction at 37 OC.
Results of DMR6
DMR6 has 1026 base pairs with a molecular weight of 41 kDa. The correct sequence of
the gene is mentioned in Appendix 1. This gene was successfully cloned into all vectors and
further expression was studied. DMR6 cloned in Tom15b was found over-expressing in
insoluble fraction when induced with 0.5 mM IPTG. In pET17b, the cloning was not successful
and further expression studies could not be carried out.
After cloning into pET20b, some fraction of the protein seemed to express in the soluble
fraction but when large scale purification was done and the concentration was checked, the
protein was less than 0.05 mg/mL rendering it impossible to determine its rate of activity. When
the protein was sub-cloned into pMALc4xA2 and sent for sequencing, the sequence was not
correct. Nevertheless, we were able to conclude that the protein is highly insoluble. We further
attempted to increase the solubility by mutating the protein and cloning it into pMALc4xA2;
however, my attempts were not successful.
L UIP IP UIS IS
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Figure 5.13: Amplification results of DMR6 gene. The first lane contains 100bp DNA ladder.
The last lane contains the amplified DMR6 which corresponds to nearly 1100 bp.
Figure 5.14: DMR6 cloned in to Tom15b vector and the extracted plasmid was amplified using





Figure 5.15: Amplification of the mutated pMALc4xA2 vector. The first lane is a 100 bp ladder
and the next lane with a dark band corresponds to the actual size of the vector pMALc4xA2
(template). The next lane is a band showing pMALc4xA2 (template) after digestion with
restriction enzymes NdeI and SalI before cloning with DMR6 (double digested). The last lane
contains the pMALc4xA2 after amplifying with vector specific primers to amplify only a region
of the gene which corresponds to nearly 1kb size.














Figure 5.17: Randomly mutated DMR6. The first two lanes contain the markers and the third
and fourth lane contains the high frequency and medium frequency mutations respectively.
Figure 5.18: Solubility Screening of DMR6 in Tom15b at various induction time at 37 ̊ C in M9
minimal medium. The first lane corresponds to the protein marker. Lanes 2, 3, corresponds to
IP1, IS1 after 1 hr induction with 0.01 mM IPTG in M9 minimal medium. Lanes 4, 5
corresponds to IP2, IS2 after 1 hr induction with 0.05 mM IPTG. Lanes 6, 7 corresponds to IP3,
IS3 after 1 hr induction with 0.1 mM IPTG. Lanes 8, 9 corresponds to IP4, IS4 after 1 hr




L IP1 IS1 IP2 IS2 IP3 IS3 IP4 IS4 IP5 IS5 IP6 IS6 IP7 IS7
DMR6 DMR6
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IPTG. Lanes 12, 13 represents IP6, IS6 after 2 hr induction with 0.05 mM IPTG. Lanes 14, 15
represent IP7, IS7 after 2 hr induction with 0.1 mM IPTG.
Figure 5.19: Solubility Screening of DMR6 in Tom15b at various induction time at 37 OC. Lane
1 represents protein marker followed by lanes 2 to 15 representing IP8, IS8 after 2 hr induction
with 0.5 mM IPTG; IP9, IS9 after 3 hr induction with 0.01 mM IPTG; IP10, IS10 after 3 hr
induction with 0.05 mM IPTG; IP11, IS11 after 3 hr induction with 0.1 mM IPTG; IP12, IS12
after 3 hr induction with 0.5 mM IPTG; IP13, IS13 after 6 hr induction with 0.01 mM IPTG;
IP14, IS14 after 6 hr of induction with 0.05 mM IPTG respectively.
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Figure 5.20: Solubility Screening of DMR6 in Tom15b at various induction time at 37 OC (lanes
2 to 5) and 25 OC (lanes 6 to 15).  Lane 1 represents protein marker. Lanes 2 to 15 corresponds to
IP15, IS15 after 6 hr induction with 0.1 mM IPTG; IP16, IS16 after 6 hr induction with 0.5 mM
IPTG; IP17, IS17 after overnight induction with 0.01 mM IPTG; IP18, IS18 after overnight
induction with 0.05 mM IPTG; IP19, IS19 after overnight induction with 0.1 mM IPTG; IP20,
IS20 after overnight induction with 0.5 mM IPTG; IP21, IS21 after overnight induction with 1
mM IPTG. All the overnight expression was carried out at lower temperature (25 OC).
Figure 5.21: Overexpression of DMR6-pET20b in BL21. From left, UIP, IP, UIS, IS after 3
hours of induction using 0.5 mM IPTG at 37OC in LB broth containing appropriate antibiotics.
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Figure 5.22: Nickel affinity purification of DMR6-pET20b. From left the lanes corresponding
are protein marker in lane 1, purified protein fractions in lanes 2-7, Wash fractions in lane 8-
10(F1, F2, F3), Induced pellet, Induced supernatant, ladder.
(a)
L Purified protein fractions F1 F2 F3 IP IS L
L
IP1 IS1 IP1 IS1 IP1 IS1 IP
1
IS1 IP2
0.01mM 0.05mM 0.1mM 0.5mM 0.01mM
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Figure 5.23: Solubility screening of DMR6 in Tom15b vector. Screening was performed at 37
OC and 25 OC at different time intervals starting from 1, 2, 3 and 15 hrs induction with M9
minimal medium. The first gel (a) shows Protein marker, IP_1, IS_1 after induction with 0.01
mM, 0.05 mM, 0.1 mM and 0.5 mM IPTG, IP_2 induced with 0.01 mM IPTG in order
respectively. The gel picture (b) shows ladder, IS_2 after induction with 0.01 mM IPTG, IP_2,
IS_2  induced with 0.05 mM, 0.1 mM, 0.5 mM IPTG, IP_3, IS_3 induced with 0.01 mM, 0.05
mM, 0.1 mM and IP_3 induced with 0.5mM IPTG respectively. The gel picture (c) shows ladder,
IS_3 induced with 0.5 mM IPTG, IP_6, IS_6 induced with 0.5 mM IPTG, IP_15, IS_15 induced
with 0.05 mM, 0.1 mM, 0.5 mM IPTG respectively. The cells induced for long hours of
(b)
(c)
L IS2 IP2 IS2 IP2 IS2 IP2 IS2 IP3 IS3 IP3 IS3
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expression were incubated at lower temperatures of 25 OC. The numbers following the IP and IS,
indicates the number of hours of induction.
Figure 5.24: LDOX expression in pET15b vector and BL21 cell lines after induction with 0.5
mM IPTG at 37 OC and 6 hr induction time.
Figure 5.25: LDOX Expression at 30 OC with 0.5mM IPTG after 3 hours induction. From left,
lane 1 to 4 - uninduced pellet (UIP), Uninduced supernatant (UIS), induced pellet (IP), Induced
supernatant (IS), lanes 5, 6- protein marker, lanes 7-10 duplicate of UIP, UIS, IP, IS.
L IP IS UIP IP IP IS UI
PIP
UIP UIS IP IS L L UI
P UIS IP IS
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Figure 5.26: LDOX expression at 18 OC with 0.5mM IPTG. Lane 1 represents protein ladder.
Lanes 2-5 represents Uninduced pellet (UIP), Uninduced supernatant (UIS), Induced pellet (IP),
Induced supernatant (IS).
Cloning results of HCT
HCT is a 1302bp gene which is shown in the agarose gel picture (fig 5.27). We attempted
to clone HCT in Tom15b, but the cloning procedure was not successful. So we could not further
proceed any other protocol with this gene.
Figure 5.27: Figure showing amplification of HCT. The first lane shows a 100 bp ladder and the
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Amplification results of Pseudomonas aeruginosa polyketide synthase (PhID)
Figure 5.28: Amplification result of Pseudomonas polyketide synthase, PhID. The gene size






Based on the enzyme assay carried out for the enzyme EfaroB, we were not able to
monitor any detectable activity. Hence, we could not screen for the inhibitors from the available
library of compounds. Nonetheless, these flavonoids were found to have some inhibitory effect
at least in micromolar range (µM) on the other enzymes of the Shikimate pathway, as tested by
my colleagues.
We have tried cloning, expressing and purifying nearly 10 genes for further use as
modifying enzymes in combinatorial biosynthesis. Of these 10 enzymes, only CI3, DMR6 and
LDOX were successfully cloned and during expression studies, only CI3 and DMR6 were
expressing, but CI3 was insoluble and DMR6 was very slightly soluble after complementation
in β-galactosidase. We attempted to enhance the solubility of these genes in different vectors
such as pET15b, Tom15b, pET17b, pET20b and pMALc4xA2. Although the vector pET20b was
found to increase the expression level, no evident increase in the protein solubility was observed
in these different constructs.
In our next attempt we exploited the varying growth conditions to reduce the rate of
protein expression and to monitor the exact condition where the protein is expressed in its
soluble form. Protein expression was also carried out in M9 minimal medium where only
negligible amount of protein expression was observed when compared to the growth in LB
medium.
Our last attempt was to introduce random mutations into the genes CI3 and DMR6,
respectively. Once solubility is favoured, we planned to test for its activity. Results show that
solubility is not favoured by these mutation because either the number of mutations would not be
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enough for the protein to express in soluble fraction or the gene might not have been inserted in
the translational frame with the pMALc4xA2.
Finally with the little amount of protein (DMR6) expressed in soluble fraction by the
pET20b vector, I proceeded with the large scale expression of DMR6 and concentrated the
protein. But since the yield and concentration was negligible, further optimization might be
required to increase the solubility.
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Chapter 7: Future work
The aim of this project is to develop an inhibitor against the Shikimate pathway enzyme,
dehydroquinate synthase (EFaroB). From our results, it is quite obvious that the concentration of
the protein was not enough for detection of its activity. Hence further optimization of the protein
needs to be done for detecting its activity, in order to inhibit the protein using our available
library of compounds
Also, neither the structure of DMR6 nor its function is known, it would be feasible to
explore the gene for its structural and functional studies. Although many homologues of
Chalcone isomerases have been widely studied, the gene of interest in our study, CI3 from
Arabidopsis, has no structural evidence reported till date. So exploring the structural details and
furthermore the functional aspects of these proteins might aid in using these proteins as
modifying enzymes in the process of combinatorial biosynthesis.
The structure and function of LDOX has been studied earlier but the results for
expression were not reproducible when attempted. Further optimization is required for increasing
the expression and solubility of the protein.
Once the solubility of the gene is enhanced using β-galactosidase α-complementation, we
had proposed to assay for the β-gal activity for the mutants. Our proposal included the addition
of the spectrophotometric substrate O-nitrophenyl- β-D-galactopyranoside (ONPG) to detect the
β-gal activity by measuring the absorbance at 420 nm in a Spectrophotometer. ONPG, although a
colourless substrate, is hydrolyzed to a yellow coloured product, nitrophenol by the β-
galactosidase enzyme.
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The rate of activity for EFaroB has to be determined for which further optimization in
increasing the yield of protein is required. Once the rate of activity is detected, we can use the
inhibitors in our lab to identify the compounds which can act as inhibitors against the enzyme
and also the concentration of these inhibitors needed to inhibit the enzyme can be measured.
Further, modifying enzymes purified can be used to make modification in the identified
inhibitors to enhance the efficiency of those inhibitors.
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Despite the conventional remark that enzymes are specific biocatalysts, it is also possible
to exploit enzymes to catalyze other relevant or irrelevant reactions instead of the original
function for which they are physiologically specialized or evolved for. This property of an
enzyme is called its promiscuity, which forms the basis for functional plasticity. Promiscuity is a
key factor in evolution of new proteins performing new functions, as it serves as evolutionary
starting points and highlight the unique evolutionary features of promiscuous enzyme functions.
By understanding how enzyme structures evolve through the study of enzyme families,
superfamilies, and suprafamilies, one can decipher and closely examine how enzymes, through
nature itself, can achieve astonishing catalytic proficiencies. Having knowledge of these nature’s
strategies, it is possible to replicate similar mechanisms in the laboratory setting to evolve new
catalysts and engineer novel protein folds to catalyze closely related or novel functions.
“Genomic enzymology”[57] is a term used by Gerlt and Babbitt to describe the expansive
strategy made possible to understand the interdependence of structure and function in enzymes
thereby gaining insight into the hidden constraints that nature has engineered into a given
structural template [57]. This necessitates the incorporation of structural and functional studies of
homologous enzymes.
In this project we aim to study the mechanism of Orotidine-5’-monophosphate
decarboxylase (OMPDC) by using the template of its related-suprafamily member, 3-keto L-
gulonate 6-phosphate decarboxylase (KGPDC).
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8.1 Opportunistic Enzyme evolution
Over the years, random genetic mutations occur within an organism’s genetic code, of
which, beneficial mutations are preserved, that may be crucial for survival. Nature is an
opportunist in expanding its biochemical repertoire through the process of natural evolution.
According to Wise et al. (2002), an enzyme’s evolution might be attributed to two
complementary strategies: either to catalyze a new transformation of the same compound,
gaining the next step in a nascent metabolic pathway or the subtle shift occurring in a substrate-
binding site might lead to an altered function of an enzyme in order to retain the aspects of the
original chemistry, thereby retaining the originality of the reaction [58].
Our project focuses on directed evolution of enzymes which mimics the natural evolution
in vitro, by operating on a molecular level where no new organisms are created and a sharp focus
is laid on specific molecular property only. Consequently, the basic concepts of diversification,
selection and amplification are maintained in directed evolution.
8.2 Functionally diverse Enzyme Suprafamilies
Suprafamily of enzymes share very little sequence identity (less than 20%) but retain
their common (β/α)8 barrel. The OMPDC suprafamily of enzymes contain four enzymes
identified till date, including: Orotidine-5’-monophosphate decarboxylase (OMPDC)  that
catalyses the conversion of Orotidine monophosphate (OMP) to Uridine monophosphate(UMP)
in the de novo synthesis of pyrimidines; 3-ketogulonate 6 phosphate decarboxylase (KGPDC) is
another member of OMPDC suprafamily catalyzing the conversion of 3-ketogulonate 6-
phosphate (KGP) to L-xylulose-5-phosphate in the fermentative utilization of L-ascorbate in a
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few enteric bacteria; and D-arabino-hex-3-ulose 6-phosphate synthase (HPS) and D-ribulose 5-
phosphate 3-epimerase (RPE).
A sequence alignment of the suprafamily of enzymes, OMPDC and KGPDC
respectively, shows the conservation of key residues of the active site (Figure 15.2). Both
OMPDC and KGPDC belong to the (β/α)8 barrel family of enzymes. Despite conservation of the
positions of a few functional groups among these suprafamily members, the active site residues
differ in the identity and mechanistic utility. Accounting for this diversity, we try to exploit the
KGPDC scaffold by mutating the critical residues that would result in an OMPDC-catalyzed
reaction.
8.2.1 3-ketogulonate 6-phosphate decarboxylase (KGPDC)
3-ketogulonate 6-phosphate decarboxylase (KGPDC) is an enzyme involved in the L-
ascorbate utilization of certain microorganisms. This enzyme catalyzes the conversion of 3-
ketogulonate 6-phosphate to L-xylulose 5-phosphate and carbondioxide [23]. The reaction
catalyzed by KGPDC is a metal-ion dependent mechanism and it involves Mg2+ for the
formation and stabilization of intermediates. Till date nearly 14 structures of KGPDC has been
deposited in PDB. The structure of wildtype KGPDC bound to L-gulonate 6-phosphate is shown
in Figure 8.2. The reaction catalyzed by KGPDC is shown in Figure 8.1.
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Figure 8.1: Reaction catalyzed by KGPDC through the formation of an enediolate intermediate.
The picture is generated using chemdraw originally adopted from [1].
Figure 8.2: Figure showing KGPDC from E. coli. The file was obtained from PDB and the
picture generated using Chimera.
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8.2.2 D-Arabino-Hex-3-ulose 6-phosphate synthase (HPS)
D -Arabino-Hex-3-ulose 6-phosphate synthase (HPS) is another remarkable member of
the OMPDC suprafamily. This enzyme is involved in the formaldehyde assimilation in the
ribulose monophosphate pathway (RuMP). HPS catalyzes the aldol condensation between D -
ribulose 5-phosphate and formaldehyde to form D -arabino-Hex-3-ulose 6-phosphate. The
evidence that HPS belongs to the OMPDC suprafamily is shown by sequence homology results
[24, 25]. Not much is explored regarding this enzyme structure and till date very little structural
information is available. Even so, it has been thought that even this enzyme might possess a
(β/α)8 barrel just like the other members of the suprafamily [23]. The mechanism catalyzed by
this enzyme is dependent on the Mg2+ just like KGPDC and the reaction proceeds via the 1,2-
enediol formation as shown in Figure 8.3.
Figure 8.3: Reaction catalyzed by HPS shows that the reaction mechanism is similar to the
KGPDC in that both requires a metal ion for the catalytic activity.
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8.2.3 D-ribulose 5-phosphate 3-epimerase (RPE)
The last member of the OMPDC suprafamily of discussion here is D -ribulose 5-
phosphate 3-epimerase (RPE). As the name suggests, this enzyme catalyzes the epimerization
reaction of D -ribulose 5-phosphate to D -xylulose 5-phosphate. This mechanism operates in the
pentose phosphate pathway. Just like other suprafamily enzymes there is structural evidence to
prove the existence of a similar (β/α)8 fold in these enzymes [26, 27]. Now the enzyme is
characterized biochemically and the evolutionary origins are also revealed by Akana (2006). The
mechanism catalyzed by RPE is metal ion independent and it binds the same substrate as HPS, D
-ribulose 5-phosphate, catalyzing an epimerization reaction. There are 6 RPE structures currently
available with PDB and the protein structure is shown in Figure 8.5. RPE is a dimer of  (β/α)8
fold as seen from the figure. There has recently been controversy regarding the metal-ion
dependence of the enzyme as Streptococcus pyrogenes RPE is activated by Zn2+ metal ion. The
reaction catalyzed by RPE is shown in Figure 8.4.
Figure 8.4: Reaction catalyzed by RPE. The substrate for RPE and HPS is the same but RPE
catalyzes the epimerization of D -ribulose 5-phosphate to D -xylulose 5-phosphate.
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8.3 Beta-alpha barrel
Nearly 10% of the structurally characterized proteins expectedly possess the classical
(β/α)8-barrel fold, at least for one domain [28]. The barrel has a cylindrical core that is
contributed by eight (β/α)-units hydrogen bonded to each other with the central core occupied by
the β-strands and the α-helices located at the periphery. The hydrophobic cores are located
between the β-sheets and the flanking α-helices, thus forming four quarter barrels [(β/α)2-
subdomains] [29]. These (β/α)8-barrel scaffold might have evolved by a two-fold gene
duplication where two identical half-barrels would have formed at the end of first duplication
and subsequent fusion of these half-barrels and the second gene duplication might usually result
in homologous enzymes that might perform distinct functions. Structural evidence for the
evolution of (βα)8-barrel fold from the half barrel through a series of gene duplification comes
from the works of Hocker and coworkers [30, 31].
Since this (β/α)8-barrel is thought to provide a structural platform for the divergent
evolution of enzymes[32], this scaffold can be well-suited for evolution of function by choosing
an appropriate active site architecture and exploiting its functional plasticity to catalyze a
particular function.
The following chapters deal with the functionally distinct enzyme suprafamilies of the
enzyme OMPDC and our attempts to elucidate the mechanism of OMPDC-catalyzed reaction on
a KGPDC scaffold by rational design by mutating the critical residues of KGPDC enzyme to
catabolize the OMPDC-catalyzed mechanism, in a hope of understanding the reaction
mechanism of OMPDC.
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Figure 8.5: Crystal structure of RPE obtained from PDB (1RPX) displaying a classical (β/α)8-
barrel fold. The structure is generated using Chimera.
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Chapter 9: Orotidine 5’-monophosphate decarboxylase (OMPDC)
9.1 Orotidine 5’-monophosphate decarboxylase
Orotidine 5’- monophosphate decarboxylase, is one of the most remarkable enzymes that
catalyze the conversion of Orotidine 5’-monophosphate (OMP) to Uridine 5’-monophosphate
(UMP) (Fig 9.1), a precursor involved in the synthesis of pyrimidines downstream of the
pathway. OMPDC is an extremely proficient enzyme, in that, unlike other decarboxylases,
OMPDC doesn’t require any metals or cofactors for catalyzing a reaction with a higher rate
enhancement of 1017. Although a detailed interrogation has been made in various studies to
explain the mechanism of OMPDC-catalyzed reaction, the actual mechanism is still under debate
and remains contentious. Based on the understanding of the previous work, we endeavor to shed
light on the mechanism of OMPDC by replicating the reaction of OMPDC on an evolutionarily
related enzyme’s scaffold.
Figure 9.1: Reaction catalyzed by OMPDC shows that the substrate OMP is converted to UMP
through the formation of vinyl carbanion intermediate. The structure is generated using
Chemdraw.
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9.2 Structural information of OMPDC
Assuming that there is a concept of “conservation of catalysis” during protein evolution,
we chose an appropriate template, as a means of imitating nature to utilize the mechanistically
diverse suprafamily of enzymes. So the enzyme we employed in our studies is 3-keto L-
gulonate-6-phosphate decarboxylase (KGPDC) from the L-ascorbate utilization pathway.
KGPDC belongs to the OMPDC suprafamily of enzymes which shares a common (β/α)8 fold, a
characteristic of this family. Although the enzyme originally lacks the activity for our target
enzyme, the active-site scaffold would be re-wired, that, with very few mutations, we can
consequently achieve the catalysis of the required target reaction. The conserved active site
architecture has restrained the evolution in the OMPDC suprafamily. Although OMPDC and
KGPDC shares less than 20% identity in their primary amino acid sequence, with no common
mechanistic attribute, it still did not go unnoticed. The common active site architecture shared
among these two enzymes is evident.
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Figure 9.2: OMPDC of Methanobacter thermoautotrophicum. The protein structure is available
in PDB and the above picture was generated using Chimera.
9.3 Previously proposed mechanisms of catalysis of OMPDC-catalyzed
reactions
Although there are several proposals suggested by various groups of researchers to
explain the mechanism catalyzed by the OMPDC enzyme, till date, there is no single proposal
that is widely accepted.
The first attempt to explain the mechanism of OMPDC-catalyzed reaction was by
Silverman and Groziak (1982) who proposed an addition-elimination reaction on the C5 carbon
where they explained the attack of a nucleophile to stabilize a bond. Silverman and Groziak
proposed an addition-elimination reaction in which a nucleophile on the enzyme forms a
covalent bond at C5 and protonates C6 [33]. Concurrent loss of the 4 carboxylate as carbon
59
dioxide and the nucleophile would yield product UMP without the formation of an anionic
intermediate. However, no kinetic isotope effect was observed for isotopically labeled 5-13C or
5-2H OMP, eliminating nucleophilic attack at C5 as the mechanistic pathway (Fig 9.3a).
Another proposal put forward a concerted protonation and decarboxylation that would
bypass the generation of a high energy anionic intermediate [34, 35] (Fig. 9.3b). D2O solvent
kinetic isotope effects and 13C labeled carboxylate kinetic isotope effects showed that
decarboxylation, determined to be the rate-limiting step, was separate from protonation
(Acheson, 1990). In 50/50 D2O/H2O the measured product isotope effect is unity (i.e. equivalent
amounts of protonated and deuterated product were observed spectroscopically), providing
further evidence that protonation does not help initiate nor is concurrent with the rate
determining step [36]. Additionally, a 102 -fold rate enhancement of decarboxylation and H6
exchange for 5-fluoroOMP and 5-fluoroUMP indicate an anionic intermediate that is stabilized
by the inductively electron withdrawing fluorine (Fig. 9.3b) [37]. Overall, accumulated
experimental evidence favors a two step reaction with a negatively charged intermediate over the
concerted reaction. Several propositions utilized protonation as a means to stabilize the anionic
charge of the intermediate since. Beak and Siegel (1976) suggested a zwitterionic or ylide
mechanism where protonation of O2 yields a positively charged quaternary amine at N1 that
could inductively stabilize the neighboring negative charge on C6 (Fig. 9.3c). A similar
zwitterionic intermediate is found in thiamin pyrophosphate-catalyzed reactions.
Lee and Houk proposed a similar delocalization scheme in which the anionic
intermediate forms a carbene resonance structure with charge delocalized to O4 (Fig. 9.3d) [33].
Their proposal suggested that a conserved lysine, aided by a hydrophobic protein interior,
transfers a proton to O4 to yield a neutral intermediate. It was also noted that the transition state
60
analogue 6-hydroxyUMP (BMP, Fig. 9.3b), a remarkably strong inhibitor with a Ki of 9x10-12 M-
1 for yeast OMPDC, not only mimics the anion at C6, but can also generate an anion at O4
similar to the Lee and Houk intermediate (Fig. 9.3b).
However, in the year 2000, four crystal structures of OMPDC, from E. coli, M.
thermoautotrophicum, S. cerevisiae, and P. falciparum, were published simultaneously. O2 and
O4 form hydrogen bonds with the enzyme and play an important role in binding and in
orientation of the substrate. However, the crystal structures showed that neither O2 nor O4 have
nearby acidic proton donors, signifying that neither oxygen becomes fully protonated. 15N kinetic
isotope effect studies performed with the 15N-labeled picolinic acid show no bond order change,
which contradicted the formation of a quaternary ammonium intermediate at or before
decarboxylation, and was the final death knell for the zwitterionic mechanism. Today, with the
wealth of knowledge available, we attempt to arrive at a possible mechanism for the OMPDC-
catalyzed reaction.
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Figure 9.3: Different mechanistic proposals for the reaction catalyzed by OMPDC. The structure
was drawn using Chemdraw based on the information published by Miller(2002) [33]
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Figure 9.4: The paradigm of Directed Evolution of enzymes. Iterative rounds of mutation and
selection will give rise to the target enzyme.
The abundantly available crystal structures of OMPDC reveal that the residues of the
conserved DxKxxD motif point toward the C6 carboxylate group. The functional significance of
the two conserved aspartates is unclear, and this discovery prompted Wu et al. to suggest that
OMPDC utilizes ground state destabilization. The concept of ground state destabilization
originates from the Circe effect introduced by Jencks. Wu et al. proposed that the positively
charged lysine allures the substrate carboxylate into the proper active site conformation, but the
neighboring negatively charged aspartates provide electrostatic stress that encourages
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decarboxylation. The strain is felt only by the Michaelis-Menton complex, thereby decreasing
ΔΔG between the ground state and transition state. However, the hypothesis for ground state
destabilization was explained by Florian et al., who stated that desolvation costs outweigh
destabilization benefits[38]. Although the catalytic rate would increase with the increase in the
hydrophobicity, desolvation would increase KM and consequently kcat/KM would not improve.
Ground state destabilization of the enzyme-substrate complex could utilize
conformational changes to position the conserved aspartates effectively. The costs of desolvation
or structural changes towards a catalytic conformation could be compensated by the intrinsic
binding energy of the phosphate group. OMPDC decarboxylates the orotidine analogue 1-
(erythrofuranosyl)orotic acid (EO) very slowly—kcat/KM is 2.1 x 10-2 M-1s-1. In the presence of
phosphite dianion, EO decarboxylation accelerates almost 105-fold. Restoration of the
phosphoryl moiety reconstitutes the original OMP kinetics, provided that the entropic effect of
binding two substrate pieces is taken into account. Catalytic activation by the addition of
phosphite supported the Jencksian concept that enzymes redirect binding energy to “pay for
catalysis”. In spite of extensive interrogation, the drive behind OMPDC catalysis is not
completely clear and remains contentious. In reality the enzyme probably uses multiple elements
to decarboxylate OMP, of which two possible mechanisms are described herein: carbene-like 8
resonance facilitated by hydrogen bonding—rather than proton transfer—and hydrophobic
destabilization of the OMP carboxylate group. Mechanistic hypotheses explored in this thesis
examine OMPDC from M. thermoautotrophicus as a model enzyme.
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Aim of our project:
To elucidate the reaction mechanism catalyzed by the enzyme Orotidine 5’-
monophosphate decarboxylase (OMPDC) on the scaffold of its related suprafamily member, 3-
keto-L- gulonate 6- phosphate decarboxylase (KGPDC).
9.5 Our hypothesis for the mechanism of OMPDC-catalyzed reaction
In our hypothesis, we propose that the OMPDC catalyzed mechanism proceeds via the
formation of a vinyl carbanion intermediate and the detailed mechanism deduced based on the
previous studies, is as follows: as soon as the substrate is captured, the substrate binding group
closes over the substrate thereby allowing the substrate to be held in its place. The residues for
the substrate binding loop is contributed by the seventh β-strand and fifth β-strand and the
corresponding residues actively participating in this step is glutamine  (Q185 in Methanobacter
OMPDC) and serine (S127 in Methanobacter). This loop closure is due to the hydrogen bonding
between the Q185 to 5’-phosphate and O2 of pyrimidine and the N3 of S127. After the substrate
is captured, the carboxylate group of OMP substrate is positioned proximal to the active site
residues aspartate (D70 in Methanobacter) and lysine (K72 in Methanobacter) from the first
domain and another aspartate (D75 in Methanobacter) from the second domain. The carboxylate
groups of OMP and the aspartate (D70) experiences an electrostatic repulsion and as a result, the
substrate destabilization occurs, thereby initiating the decarboxylation reaction. The removal of
the carboxyl group might be responsible for the formation of a high-energy intermediate, and the
ensuing transition state stabilization follows. This might be initiated by the lysine residue (K72)
by stabilizing the negative charge imparted on the cleavage of carboxylate group. This function
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of lysine in stabilizing the transition state is a probabilistic explanation for the enzyme catalysis
in the absence of metals and cofactors, with a high proficiency.  The final step in the mechanism
is the product formation and subsequent release if the product, UMP. The phosphate group of the
substrate binds to the phosphate binding loop as evidenced in the literature. The schematic
explanation of this hypothesis is shown in the figure below (Fig 9.5).
9.5 Selection of KGPDC as a template to explore the mechanism of
OMPDC-catalyzed reaction
KGPDC is a member of the OMPDC suprafamily and it shares the conserved active site
architecture but catalyze a chemically-distinct reaction. The reaction of KGPDC involves the
conversion of 3-keto L-gulonate 6-phosphate to L-xylulose 5-phosphate. Unlike OMPDC, this is
a metal dependant enzyme which depends on Mg2+ for its activity. Although both are
decarboxylation reactions, the presence of water molecules on si and re face of the intermediate
supply the necessary protons for product formation, in the case of KGPDC, while the source of
protonation is explained by the presence of a lysine residue in OMPDC. Structure based
sequence alignment of KGPDC and OMPDC reveals the critical residues involved in the
catalysis of the respective reactions. The DKD motif is conserved in both OMPDC and KGPDC.
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Figure 9.6: Structural Superposition of Methanobacter OMPDC and E.coli KGPDC.
Figure 9.7: Superimposed structures of OMPDC and KGPDC showing conserved active site
residues.
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Table 1: Mutants based on the differing active site residues between KGPDC and OMPDC.
Based on the structure based sequence alignment of OMPDC and KGPDC, differing
catalytic residues are shown in Table 1 above. With the expectation that the differing catalytic
residues might account for the difference in the mechanism of each of these enzymes, mutations









Figure 9.8: Sequence alignment of KGPDC and OMPDC.  The sequences of the four
orthologues of KGPDC SgaH (from E. coli), KEF (Enterococcus fecalis), KSP (Streptococcus
pneumonia) and KST (Salmonella typhimurium) with the OMPDC of Human, yeast,
Methanobacterium and Plasmodium are shown, respectively. It is evident that the D-K-D motif
and R203 are conserved throughout the suprafamily and highlighted in red. The differing
residues are highlighted in other colours.
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Chapter 10: MATERIALS AND METHODS
In our study we selected four orthologues of KGPDC from Escherichia coli (SgaH),
Enterococcus faecalis (KEF), Salmonella typhimurium (KST) and Streptococcus pneumonia
(KSP), respectively, for mutational studies. The OMPDC orthologue from Methanobacter
thermoautotrophicus (MtOMPDC maintained on a pET15b vector) was used as a control.
10.1 Site-Directed mutagenesis
The frozen stocks of the enzymes were verified for its correct sequence after plasmid
extraction.  The table describes the primers used for mutation. Site directed mutants of KGPDC
were constructed using Quikchange kit (Stratagene), according to manufacturer’s instructions.
The method uses a double-stranded DNA vector with the insert in context and a set of primers
complementary to opposite strands of the vector. Temperature cycling using the primers
generates a mutated plasmid containing staggered nicks.
A typical reaction (50 µL) contains 30 ng of plasmid template, 5 µL of 10X Pfu ultra
amplification buffer, 125 ng of each complementary primers, 0.2 mM of each of the four dNTPs
and 2.5 U of PfuUltra DNA polymerase. The mutated plasmid was generated using the following
parameters: 95 OC for 30 sec, followed by 18 cycles of 95 OC for 30 sec, 55 OC for 1 min and 68
OC for 17 min. Following temperature cycling, the products were incubated with 1 µL of DpnI
endonucleases (Stratagene) and incubated at 37 OC for 2-3 hours. DpnI being specific for
methylated and hemi-methylated DNA digests the parental DNA, thus allowing the selection of
mutation containing synthesized DNA. This is followed by dialysis at room temperature for 30
min and transformation in to XL1-Blue competent cells. The plasmids were extracted and
transformed in to BL21 cells for expression.
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These single mutants are used as templates for creation of double and triple mutants. The
mutant primers employed in the study are designed based on the instructions given in
Quikchange protocol and the corresponding sequences of primers are shown in appendix 3.
10.2 OMPDC-negative E.coli selection strain (WSY102)
The OMPDC-negative E.coli selection strain (WSY102) was constructed using the
method described by Datsenko and Wanner [39] and the frozen stocks were available in our lab
using which the electrocompetent cells were prepared according to the methods mentioned
earlier.
10.3 Transformation of mutants into WSY102
The mutants were transformed into WSY102 competent cells, in the same way as
transformation carried out in an XL1-Blue competent cells and plated on to LB agar plates
containing the antibiotics Ampicillin (100 µg/mL), Chloramphenicol (25 µg/mL) and
Kanamycin (50 µg/mL). These plates were incubated overnight at 37 OC.
10.4 Complementation growth studies
In our study, we undertook a very powerful selection strategy for exploring the correct
mutants of KGPDC that can be complemented to perform the OMPDC-catalyzed reaction.  We
used the wild-type orthologues of KGPDC which included SgaH, KEF, KSP and KST,
respectively, for our experiments. The OMPDC orthologue from Methanobacter was used as a
control .
The mutated strains were grown in M9 minimal medium and the aerobic growth was
monitored. The aerobic growth studies in liquid cultures were performed at 37 OC. The colonies
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obtained from the LB agar plates were grown in LB broth containing the antibiotics Ampicillin
(100 µg/mL), Chloramphenicol (25 µg/mL) and Kanamycin (50 µg/mL). This overnight culture
is pelleted and the pellet was resuspended in 1X M9 minimal salts medium and subcultured in
1X M9 minimal medium containing glucose and one set without glucose to serve as control.
Aliquots of 30 µL was inoculated into 13x100 mm borosilicate glass culture tubes (Fisher
Scientific) fitted with steel lanced culture tube closures containing 3 mL of 1X M9 minimal
medium containing 50 mM glucose, 1 mM IPTG and 100 µg/mL Ampicillin.
The cell density of the aerobic growth was measured at OD600 using a
Spectrophotometer. We also plated the cultures on to M9 minimal agar medium containing
50mM glucose, 1mM IPTG and 100µg/mL Ampicillin and incubated the plates at 37 OC within
humidified boxes.
The results of the readings measured during the aerobic growth study were plotted as a
graph using MS-excel against the time scale.
10.5 Purification of Methanobacter OMPDC
The OMPDC-pET15b clone was obtained from the laboratory and the purification of
MtOMPDC was followed according to previously described protocol by Wood (2009). The
MtOMPDC in pET15b vector was transformed into BL21 and the liquid culture of LB
containing the transformed MtOMPDC in pET15b was over-expressed with 0.5 mM IPTG and
incubated for 18 hours at 37 OC. The protein was purified using the nickel affinity
chromatography in an FPLC system. The purified protein was then concentrated and frozen as
pellets in liquid nitrogen. The enzyme concentration was determined at 280 nm using an
extinction coefficient of 6085 M-1 cm-1.
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Chapter 11: Results
11.1 Aerobic growth curves
11.1.1Complementation growth curve of Wildtype MtOMPDC in auxotrophic
strain (WSY102)
The OMPDC from Methanobacter serves as a control strain to study the
complementation of growth in an auxotrophic strain devoid of OMPDC activity. The presence of
the OMPDC complements the growth of the WSY102 in a M9 minimal medium. By comparing
the results of wild-type OMPDC and mutant KGPDC, the growth pattern can be observed.
Graph 1: Growth curve of MtOMPDC complemented in WSY102 auxotrophic strain and grown

















11.1.2 Complementation of growth in KGPDC mutants
11.1.2.1 Results of E33K single mutants of KGPDC
The single mutants of E33K were created using Quikchange mutagenesis as mentioned in
the experimental protocol. The results of the single mutants were verified by sequencing and the
verified clones were inoculated into M9 minimal medium to study the complementation of
growth which is indicative of OMPDC activity.
From the results, we could infer that the single mutation of E33K alone is not sufficient
to effect OMPDC activity. No significant pattern was observed in the growth of E33K mutants in
M9 minimal medium. In the graph, the blue line indicated the M9 minimal medium in the
absence of glucose and red and green colour represented the duplicate growth curves of the
mutants as observed in M9 minimal medium containing glucose.
11.1.2.1.a SgaH
















SgaH E33K mutant- WSY102- M9 Minimal
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11.1.2.1.b KEF
Graph 3: Growth curve of KEF E33K mutant-WSY102-M9 Minimal Medium.
11.1.2.1. c KSP


































Graph 5: Growth curve of KST E33K mutant- WSY102- M9 Minimal Medium.
11.1.2.2 Results of E33K/W117S double mutants of KGPDC
The single mutants of E33K were used as templates for creating  the double mutants of
E33K/W117S. The aerobic growth curve of these double mutants are shown below. The graph is
plotted after growing these orthologues in the presence of glucose. We could infer that no















KST E33K mutant- WSY102- M9 Minimal
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Graph 6: : Growth curve of E33K/W117S double mutants of SgAH, KEF, KSP and KST in
WSY102- M9 Minimal Medium.
11.1.2.3 Results of W117S/G171Q double mutants of KGPDC
The single mutants of W117S were used as a template to construct these double mutants,
the results of which are shown below. After 72 hours, we were able to detect some growth in the
M9 liquid medium with the double mutant of W117S and G171Q. In order to deconvolute these
results, we tried plating 100 µL of the culture of the mutants transformed into WSY102 onto M9
minimal agar plates and incubated in a moist chamber at 37 OC. No colonies were observed even

























Graph 7: Growth curve of SgAH W117S mutant- WSY102- M9 Minimal Medium
11.1.2.3.b KEF






































Graph 9: Growth curve of KSP W117S mutant- WSY102- M9 Minimal Medium.
11.1.2.3.d KST

































11.1.2.4 Results of E33K/G171Q double mutants of KGPDC
The single mutants of E33K were used as a template to construct these double mutants,
the results of which are shown in the following page. Just as the W117S/G171Q, the double
mutants of E33K/G171Q were showing a sluggish growth pattern after 100 hours. The blue and
red colors shown in the graph below represented the growth of these mutants in the absence of
glucose and the green and purple color represented the growth pattern observed in the presence
of 50 mM D-glucose.
The clones that were growing in the liquid medium were inoculated on the M9 agar
plates. But no colonies were observed on the plates. This time we repeated the experiment on
liquid medium again and the results were consistent with those observed earlier with liquid
medium. This ruled out the option of possible contaminants in the medium. We deduced that
these double mutation are insufficient for OMPDC activity and proceeded with selection using
triple mutants.
11.1.2.4.a SgaH























Graph 11: Growth curve of KEF E33K/G171Q double mutant- WSY102-M9 Minimal Medium.
11.1.2.4.c KSP









































Graph 13: Growth curve of KST E33K/G171Q double mutant-WSY102-M9 Minimal medium.
11.1.2.5 Results of E33K/W117S/G171Q triple mutant
The triple mutant of E33K/W117S/G171Q was constructed from double mutants and the
results are shown in the following page. The growth was observed in triple mutant but the
growth pattern was not so uniform even with duplicate copies. In one of the triple mutant
orthologues (KST) a positive growth curve was observed just like the pattern observed for wild
type OMPDC. Another orthologue, KSP did not successfully transform after triple mutation, and
also the sequencing result of the triple mutant was not correct. So we could not proceed further






















Graph 14: Growth curve of SgAH E33K/W117S/G171Q triple mutant- WSY102-M9 Minimal
medium.
11.1.2.5.b KEF
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11.1.2.5.c KST
Graph 16: Growth curve of E33K/W117S/G171Q triple mutant-WSY102-M9 Minimal
Medium.
11.2 Results for Purification of MtOMPDC
The OMPDC from Methanobacter is a 25kDa protein and is seen in the gel picture
provided below. The expression was checked at 37 OC and also 25 OC for 18 hours, the protein
over-expressing at both conditions. But for large scale purification of the protein, the
experimental protocol mentioned in the reference paper was followed and the protein was over
expressed at 37 OC for 18 hours after induction with 0.5 mM IPTG. The recombinant protein
contains 6-his tag and is purified by a nickel affinity chromatography. The results are shown in























Figure 11.6: Purification of Methanobacter OMPDC at 37 OC. The lane 1 contains the protein
ladder (L), lanes 2,3 and 4 contains the wash fractions(F1, F2, F3), lanes 5-11 contains the
purified protein, lane 12 contains the supernatant(IS), lane 13 contains the pellet(IP) and the lane
14 contains the protein marker(L).
L F1 F2 F3 Purified Protein Fractions IS IP L
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Chapter 12:Discussion
In nature, the enzymes are evolved to perform an astonishing array of reactions.
Deciphering the mechanism of catalysis of these enzymes by exploring the possibilities of
protein engineering not only serves to elucidate the function of these enzymes and the structural
insights, but also aids in the therapeutic application. There are not many proven successes in
protein engineering since this is still a relatively difficult and intractable field. One notable
success is the de novo design of the stable protein whose topology has not been observed in
nature [40].
The knowledge of structure-function relationships of the conservation of the residues in
the catalytic motifs or the active site architecture can be exploited to identify an appropriate
protein scaffold for protein engineering [41-43]. OMPDC and KGPDC belong to the active-site
architecture constrained suprafamily where the active site architecture is conserved through the
orientation and placement of residues.
In a study conducted on 24 pairs of homologous enzymes by Bartlett, 6 pairs enzymes
that share no common mechanistic attribute but with a conserved active site architecture has been
identified [44]. One of them is the OMPDC suprafamily [45, 46].
12.1 Aerobic growth of Mutant libraries
The aerobic growth curves, as observed, do not show a significant growth pattern with
the single mutant E33K. However with the double mutants of E33K and G171Q, a deliberate
growth pattern was observed after 100 hours in case of all these KGPDC orthologues, but with
no proper consistency. No growth was observed with the double mutant of E33K/W117S.
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In order to evaluate the accuracy of these results, we tried plating the E33K/G171Q
double mutants that showed a considerable growth in liquid media, onto M9 minimal agar plates.
To our disappointment, even after 2 weeks no colonies were observed on M9 plates. With this
we came to a conclusion that these mutations are not enough for the KGPDC orthologues to
complement the function of OMPDC-catalyzed reaction.
In the same way, the growth patterns observed with the double mutant of W117S/G171Q
and the triple mutant of E33K/W117S/G171Q was also rechecked for the consistency of the
results. All these provided clues that these 3 critical mutations alone are not enough for the
KGPDC orthologues to complement the OMPDC function and that further mutations are needed
which might be decided on rational basis or through an error prone PCR and subsequent
transformation of these mutated KGPDC orthologues in to the OMPDC auxotrophic strain might
allow powerful selection of a clone that can catalyze the OMPDC catalyzed reaction. Sequencing
results might reveal the critical mutations that might be needed for KGPDC to complement
OMPDC function.
12.2 Purification of MtOMPDC
The OMPDC from Methanobacter was isolated and purified according to available
protocols and we obtained a yield of 21.8 mg/mL of protein after concentration. This
concentrated protein was frozen as pellets using liquid nitrogen and stored at -80 OC to carry out
further assays.
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Chapter 13: Future work
We had planned to assay for the activity of the wild-type OMPDC enzyme in the
presence of a highly reactive fluorinated-substrate as performed earlier. Also we will perform the
assay for the mutant KGPDC soon after it is found complementing the OMPDC function. In
order to complement the function of OMPDC on a KGPDC domain, sometimes cavitation might
be required so that the bulkier substrate OMP can be accommodated in the active site which was
designed for accommodating the substrate KGP otherwise.
Further mutations might be rationally designed and also random mutagenesis using error
prone PCR can be planned and further transformation into WSY102 might allow a powerful
selection strategy for declaring the correct clone. Studies on the loop dynamics might be
necessary in the case of OMPDC and essentially the length, sequences and position of the loop,
torsional symmetry, overall topology of the loop, acceleration of the loop and the information of
hinge region of the loop. These may aid in arriving at an elucidation of the reaction mechanism
of the OMPDC-catalyzed reaction.
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PART 3: Targeted Drug Discovery against Plasmodium falciparum
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Chapter 14: Introduction
According to WHO, the morbidity and the mortality rate due to the malarial disease
increases every year and the occurrence is mainly supercilious in under-developed and
developing countries. For many years, artemisinin protracts to be an effective drug against the
malarial parasite. Due to the rampant prophylactic use of artemisinin and ACT (Artemisinin-
based combination therapies), the malarial parasite gains resistance which has been reported
recently [47-49]. In an effort to combat malaria, it is crucial that new drugs have to be developed
with novel mechanisms [4].
14.1 Aim of the project
Using the structural and sequence disparity between the Plasmodium’s OMPDC and
Human OMPDC, we propose to develop an inhibitor that specifically targets Plasmodium
falciparum’s OMPDC.
14.2 Human OMPDC
In humans, OMPDC does not exist as a monomeric enzyme but exists as a dimer of UMP
Synthase performing the reactions catalyzed by OPRTase (Orotate phosphor ribosyl transferase)
and OMPDC (Orotidine-5’-monophosphate decarboxylase). UMP synthase (UMPS) catalyzes
the last two steps of de novo pyrimidine nucleotide synthesis and has been recognized as a
potential cancer drug target.
OMPDC is contained in the C-terminal domain of UMPS. OMPDC is cofactor-less, yet is
a tremendously efficient enzyme. There have been never-ending arguments over the reaction
catalyzed by OMPDC. Recent studies of OMPDC conducted by Gerlt and their team proposes a
non-covalent decarboxylation mechanism via high-energy intermediate (vinyl-carbanion).
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Currently there are 36 crystal structures of human OMPDC deposited in RCSB-Protein
data bank (PDB) which includes the enzyme in complex with substrate, product, and nucleotide
inhibitors. Unexpectedly, simple compounds can replace the natural nucleotides and induce a
closed conformation of OMPDC [50], defining a tripartite catalytic site. In order to be used as an
efficient drug, these inhibitors must meet to maximize therapeutic effects and minimize cross-
species activity.
Figure 14.1 Human UMPS (OMPDC containing domain) showing active site architecture. The
active site residues are shown in forest green and the enzyme UMPS is shown in cyan. The right
panel shows the close up view of OMPDC bound to the substrate UMP with active site residues
colored by element using Chimera.
14.3 Plasmodium’s OMPDC
As seen in the previous part, the enzyme OMPDC operates in the de novo pyrimidine
biosynthesis pathway culminating in cytosine and thymine nucleotides. There is an alternate
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pathway to the de novo pathway which is the salvage pathway which salvages the pyrimidine
nucleotides. Some eukaryotic parasites, such as Plasmodium falciparum (the causative agent for
malaria), are able to utilize only the de novo pathway. Hence the inhibition of the intra-
erythrocytic parasite’s OMPDC which operates in the de novo pathway might be a promising
target, in an effort to combat the battle against the disease caused by the malarial parasite.
Plasmodium’s OMPDC is approximately a 38 kDa protein and studies also suggests that
the protein is a homodimer and the active site residues are contributed by the dimeric interface
[51]. Currently, there are 11 structures of Plasmodium falciparum, with and without ligands,
deposited in Protein Data Bank (PDB). These structural informations give a great wealth of
information to specifically target a drug against the malarial parasite’s OMPDC. Based on the
disparity between human and Plasmodium’s OMPDC, a drug that acts as an exclusive inhibitor
of the Plasmodium’s OMPDC which might have a minimal or no effect on its human host.
In Plasmodium parasites, pyrimidine nucleotides are synthesized de novo via a six-step
pathway. One of the steps in the de novo pathway for the biosynthesis of pyrimidines involves
the addition of a ribosyl phosphate group to orotic acid by orotate phosphoribosyltransferase
(OPRT), resulting to orotidine 5'-monophosphate (OMP). Subsequently, orotidine 5'-
monophosphate decarboxylase (OMPDC) catalyses the removal of the carboxyl group from
OMP to produce, uridine monophosphate (UMP), from which all pyrimidine nucleotides can be
derived. This decarboxylation step is accelerated by a factor of 1017 without the benefit of a
catalytic cofactor by OMPDC, making it the most efficient of all enzymes.
Despite the enormous availability of the structures of OMPDC in many organisms in apo
form and in complexes with UMP and its analogs, including 6-hydroxyuridine 5'-monophosphate
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(BMP) and 6-azauridine 5'-monophosphate (aza-UMP), the mechanism of decarboxylation of
OMP to UMP remains uncertain.
In spite of conserved active site residues and geometry, OMPDC sequences are highly
divergent (less than 30% sequence identity within the family) and split into four major
subfamilies identified by sequences and the length of the loop at the end of the 7th β strand,
which closes off the active site during catalysis.8 Although overall sequence identity can be very
low, all OMPDCs fold into a dimer of (β/α)8 barrels with precisely placed and highly conserved.
It has been suggested by Langley (2008) that the conformational flexibility observed in
the phosphate-binding loop and the β5α loop might be a reason in the sequestration of the
substrate and further release of the product[51].
Figure 14.2: Structure of plasmodium OMPDC (2FFC) bound to UMP. The protein is shown in
white while the ligand is shown in yellow. The active site residues contributing to the catalytic
activity are shown in other colours.
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Figure 14.3: Close up snapshot of Plasmodium OMPDC bound to UMP. The ligand is shown in
yellow colour and the protein is shown in grey colour. Other functional groups are: Green -Thr
225 and Thr 226 , Salmon- Lys133 and Lys169, Magenta- Gln 300, Cyan- Pro295, Orange red-
Asp41 & Asp 167 , Sea Green- Asn 135, Bubblegum pink- Arg325 .  These numberings are
according to the Plasmodium species. This image is generated from Chimera.
14.4 Inhibitors to Plasmodium OMPDC in the past
Literature studies shows that even though there are so many available inhibitors screened
for its activity, these compounds are considered unsuitable to be used as therapeutics because the
inhibitory constants (Ki) are in micromolar (µM) range and so further optimization is required
for these compounds or new compounds have to be screened for their use as effective drugs. Few








Figure 14.4: Chemical structures of  inhibitors used in the study of OMPDC [51] (a) OMP, the
substrate of OMPDC (b) UMP, the product obtained from the catalysis of OMPDC-catalyzed
reaction  (c) AzaUMP, (d) BMP, (e) Pyrazofurin 5′-monophosphate, (f) XMP, and (g)
allopurinol-3 riboside 5’-monophosphate . These structures are drawn using Chemdraw.
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Chapter 15: Species-specific design of Inhibitor
Inhibiting the pyrimidine biosynthetic pathway enzyme, OMPDC has more pitfalls than
advantages. This includes the toxic effects of  blocking the pyrimidine pathway which might lead
to blockage in the synthesis of important downstream products [53],  interference with the
immune cells that are involved in the defense mechanism of the host [54], and the risk in orotic
aciduria being induced [50] .
Time and again, it is not new to use these inhibitors as effective drug compounds against
the pathogens at least for a short-term treatment for various infections. The prime thing of focus
in using these compounds as a species-specific inhibitor should be that these compounds must
have a minimal cross-reactivity with the human host, thereby avoiding any negative impact
caused by the drug while administering for human infections.
In the past, literature work claims the activity of 6-iodo uridine to act as an anti-malarial
compound [55] by having a covalent inhibition with the catalytic lysine residue in the catalytic
triad [D-x-K-x-x-D]. since these residues are not absent from humans, being highly conserved
residues, the idea of using 6-iodo uridine as an anti-malarial compound has to be ruled out to
avoid the problems due to inadequate species-specificity.
There is a suggestion made in one work [50], to develop an inhibitor molecule by
exploiting the CO2 binding cavity by substituting the C6 carbon in order to produce a kink in the
substrate-enzyme complex (OMP-OMPDC). Also the author suggests the use of a substrate that
can be converted by OPRT in to an inhibitor compound which might target the malarial parasite
specifically.
One should also expect the tediousness in designing these inhibitors which might have a
higher potential against a specific-species. In our work, we proposed to exploit the differing
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functional residues between Human and Plasmodium, thereby the inhibitor developed is specific
against the sequence of Plasmodium meanwhile being less detrimental to the host.
15.1 Differing residues between Plasmodium and Human OMPDC enzymes
The common D-x-K-x-x-D pattern is seen in all the orthologues of OMPDC.  The
phosphate dianion binding site at R203 position is also retained and conserved throughout the
family. Albeit these commonness, there are two residues found differing between the human and
plasmodium’s OMPDC. Despite the conserved regions among all these Plasmodium species, the
phosphate binding loop is of varied length and sequence (Fig 15.2).
In the malarial structures of UMP complexes, the OD1 oxygen of an Asparagine residue
(N104) is positioned to form bifurcated hydrogen bonds with the 2′- and 3′-hydroxyls of the
ribose. The analogous residue in the human structure is a histidine (H283). The bacterial
enzymes have a Glycine at this position. Another difference is that the human enzymes have
additional Serine (S257) hydrogen bonding the 3′- hydroxyl of the ribose. This residue is
replaced by a Glycine residue in the malarial structures (G21, or an Alanine in most prokaryotic
structures), and a water molecule makes the analogous hydrogen bond. The residues N104 and
G21 of the malarial structures are replaced by H283 and S257 in the human structure (Figure
15.1). More minor differences between human and malarial enzymes include the conservative
substitution of several residues of the R5- loop (T195 replaced by S372 and N196 replaced by
S373), and a methionine residue projecting from the R5-loop (M371) of the human enzyme is
replaced by M168B from the B-subunit of the malarial enzyme (Figure 15.1) while the
corresponding position of M371 in Plasmodium is a T194 residue.
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Figure 15.1: Human and Plasmodium OMPDC differing catalytic residues [51]. The catalytic
residues N104 and G21 of the malarial structures are replaced by H283 and S257 respectively in
the human structure. The T195 residue in Plasmodium is substituted by a more similar S372.
Black colour represents the malarial OMPDC residues while pink colour represents the human
OMPDC residues. The green colour represents the product, UMP.
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Figure 15.2: Sequence alignment of OMPDC from different organisms shows a conserved DKD




From the above bioinformatics analysis of the structures of human and Plasmodium
OMPDC, very few clues are available to the species-specific inhibitor design. From the
structure-based sequence alignment, it is revealed that only two differing residues are of
considerable interest: N104 and G21. The available information suggests that the Asparagine
residue is involved in hydrogen bonding with the 2’- and 3’- hydroxyl groups in case of
Plasmodium. In the case of humans, this asparagine is replaced with a histidine in the
corresponding region. All the other bacterial species show a glycine in the same position. In the
bacterial species, not much emphasis is laid on the catalytic importance of this residue, except
the information that this residue is found near the regions of catalysis.
The next important residue is glycine that hydrogen bonds the 3’-hydroxyl of ribose
moiety in Plasmodium. In humans, this residue is replaced by serine while the bacterial species
contain an alanine in the corresponding position.
Other least important residues such as threonine, T195 (Plasmodium) which corresponds
to serine, S372 (Human) and the methionine (change in the position of the residue) are of least
importance in our topic. Since threonine and serine are related class of amino acids containing
similar functional group, we did not target these residues.
As discussed previously in part 1 of the thesis, we attempted to screen for inhibitor
compounds against the available flavonoid library in our laboratory.
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Chapter 17: Future Directions
From these initial results of Bioinformatics analysis, it is possible to conclude that we can
design small hydrophobic compounds targeting the N104 and G21 residues. It is clear from the
available information that 6-aza UMP and XMP bind preferentially to the Plasmodium’s
OMPDC when compared to human OMPDC. Hence, a further detailed analysis is required to
analyze the protein-inhibitor complex and efforts can be made to exploit the function of
OMPDC. As mentioned in the previous part of this thesis, once the mechanism of OMPDC is
clearly elucidated, it might serve as constructive information in order to study the Plasmodium’s
OMPDC enzyme.
Also, as per the suggestion by Wittmann (2008) [50], an attempt can be made to
synthesize an inhibitor compound from OPRT, thereby increasing the specificity of the drug
against Plasmodium falciparum. The availability of the library of flavonoid compounds
(Appendix 2) in our laboratory does not stop us from trying to screen these compounds as
inhibitors against the Plasmodium’s OMPDC enzyme.
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Appendix 1- List of available flavonoids in the lab
No. Name of Compound
Molecular
Weight
Y001 (-) Shikimic acid 174.16
Y002 (-)-Catechin 290.28
Y003 (-)-Epicatechin 290.28




Y008 (+) Catechin 290.28
Y009 ( Catechin 290.28
Y010 (+) Epicatechol 290.28
Y011 (+)-Taxifolin 304.27
Y012 1,2-Catechol Co-polymer
Y013 2,3-DihydroxyBenzoic acid 154.13
Y014 2,4-DihydroxyBenzoic acid 154.13




Y019 2-MethoxyCinnamic acid 178.19
Y020 2-Phenylchromone 222.24
Y021 3',4'-DihydroxyFlavone 254.25
Y022 3,4-Dihydroxyhydrocinnamic acid 182.17
Y023
3,5,7-TrihydroxyFlavone  (aka Galangin from
Extrasynthese) 270.25







Y031 4-HydroxyCinnamic acid 164.16
Y032 4-Hydroxy-Coumarin 162.15
Y033 4'-HydroxyFlavanone 240.27
Y034 4-MethoxyCinnamic acid 178.19










Y045 Alpha-MethylCinnamic acid 162.19
Y046 Apigenin 270.25
Y047 Apigenin-7-glucoside 432.38









Y057 Cinnamic acid 148.16
Y058 Coumarin 146.15
Y059 Cyanidanol-3 290.28
Y060 Cyanidin Chloride 322.7





Y066 D-Catechin Tetrahydrate 362.28
Y067 Delphinidin chloride 338.7
Y068 DihydroFisetin 288.26




Y073 Epicatechin (aka Y003) 290.28
Y074 Epigallocatechin gallate 458.37
Y075 Eriodictyol 288.27
Y076 Eriodictyol-7-glucoside 450.39
Y077 Ferrulic acid 194.19
Y078 Ferulic acid 194.19
Y079 Fisetin 286.25
Y080 Fisetinidin Chloride 306.68
Y081 Flavanone 224.27






















Y104 Leucocyanidin hydrate 324.27
Y105 Linarin 592.56
Y106 Luteolin 286.25
Y107 Luteolin 3'-7-Diglucoside 610.52
Y108 Luteolin 4'-glucoside 448.38
Y109 Luteolin 7-glucoside 448.38






Y116 Morin dihydrate 338.24
Y117 Morin hydrate 320.24






Y124 Phenylacetic acid 136.15
Y125 Phloretin 274.28
Y126 Phloridzin 436.41
Y127 Phloridzin dihydrate 472.41












Y140 Rutin ex Sarrasin (Buckwheat) 610.53
Y141 Rutinose 326.3
Y142 Sakuranetin 286.29
Y143 Sakuranetin monohydrate 304.29
Y144 Scopoletin 192.17
Y145 Silybin 482.45
Y146 Sinapic acid 224.22
Y147 Sulfuretin 270.25
Y148 Tangeretin 372.38




Y153 Veratric acid 182.18
Y154 Vitexin 432.38
Appendix  2: Nucleotide Sequences of enzymes used in the project










































































































































































































































APPENDIX 3: SEQUENCES OF MUTANT PRIMERS
Mutant Primer Sequences
KEF E33K FOR 5’-GAGAAATTGTGGATATTATCAAGGTTGGCACTATTTTGTGTTTAC-3’
KEF E33K REV 5’-GGCCTTCTTGTAAACACAAAATAGTGCCAACCTTGATAATATCCAC-3’
KSP E33K FOR 5’-GGTCAGGAAGTAGATATTATCAAAGCTGGAACTGTTTGCTTGC-3’
KSP E33K REV 5’-GCAAGCAAACAGTTCCAGCCTTGATAATATCTACTTCCTGACC-3’
KST E33K FOR 5’-GGATCATGTCGATATCGTTAAAGCCGGAACCATCCTTTGTTTAAC-3’
KST E33K REV 5’-GTTAAACAAAGGATGGTTCCGGCTTTAACGATATCGAC-3’
SgaH W117S FOR 5’-GACCGGTTACTCGACCTGGGAAC-3’
SgaH W117S REV 5’-GTTCCCAGGTCGAGTAACCGGTC-3’
KEF W117S FOR 5’-ACTATATGGAAATTCGACAATGCAACAAG-3’
KEF W117S REV 5’-CTTGTTGCATTGTCGAATTTCCATATAG-3’
KSP W117S FOR 5’-GCTTTATGGCGATTCGACTTTTGAACAAG-3’
KSP W117S REV 5’-CTTGTTCAAAAGTCGAATCGCCATAAAGC-3’
KST W117S FOR 5’-GTTCGGCAACTCGACGCTGGACG-3’
KST W117S REV 5’-CGTCCAGCGTCGAGTTGCCGAAC-3’
SgaH G171Q FOR 5’-GTCACCGGACAGCTGGCGCTG-3’
SgaH G171Q REV 5’-CAGCGCCAGCTGTCCGGTGAC-3’
KEF G171Q FOR 5’-CGTCACAGGTCAATTAACTGTCG-3’
KEF G171Q REV 5’-CGACAGTTAATTGACCTGTGACG-3’
KSP G171Q FOR 5’-CTGTAACAGGTCAACTAGATGTAG-3’
KSP G171Q REV 5’-CTACATCTAGTTGACCTGTTACAG-3’
KST G171Q FOR 5’-GATTACCGGCCAAATTACCCCAG-3’
KST G171Q REV 5’-CTGGGGTAATTTGGCCGGTAATC-3’
